The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
Open accessAbstract
Despite recent advances in the management of colorectal cancer, metastatic disease remains challenging, and patients are rarely cured. However, a better understanding of the pathways implicated in the evolution and proliferation of cancer cells has led to the development of targeted therapies, that is, agents with action directed at these pathways/features. This approach is more specific to cells within which these pathways, such as epidermal growth factor receptor (EGFR), are overactive; this is in contrast to the relatively indiscriminate mechanism by which cytotoxic chemotherapy tends to affect rapidly dividing cells, regardless of their role. Although factors unique to a given patient, such as the location of the primary tumor (sidedness) or the presence of mutations that confer resistance, may limit the utility of these agents, targeted therapies are now a part of the treatment paradigm for metastatic colorectal cancer, and survival outcomes have significantly improved. This review provides an overview of the role of targeted therapy in the management of patients with colorectal cancer metastases as well as a discussion of issues in patient selection, with a focus on inhibitors of angiogenesis, EGFR‐targeted therapy, BRAF mutation–targeted therapies, and other novel strategies, including immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“Each combination was found to be superior to 5-FU and leucovorin alone(6,7) and to have similar efficacy with a median survival of 18 to 20 months.(8,9)”
BackgroundGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37263 · Cited by 2,404
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Self-citationVan Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 1×
“Therefore, even if, for example, the excitement recently engendered by new agents with an inhibitory effect on a K-RAS-12C–mutated preclinical mCRC model(11) is affirmed in clinical trials, the impact will likely be limited to the 4% or so of patients whose tumors harbor that precise mutation.(11) Arguably, until”
BackgroundBennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · cited 2×
“0005).(23) As such, like ziv-aflibercept, ramucirumab is also approved for use in the second line in combination with FOLFIRI or irinotecan.”
BackgroundSobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
Grothey, A., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D., Hedrick, E., & Kozloff, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606
THE SYNTHESIS OF 5-FLUOROPYRIMIDINES
Duschinsky, R., Pleven, E., & Heidelberger, C. (1957) · Journal of the American Chemical Society · doi:10.1021/ja01573a087 · Cited by 510
Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., Hornbuckle, J., Peterson, M., Rees, M., Iveson, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70105-6 · Cited by 426
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Maru, D., Yan, Y., Lanman, R., Manyam, G., Hong, D. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 389
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 388
O'Neil, B. H., Allen, R., Spigel, D. R., Stinchcombe, T. E., Moore, D. T., Berlin, J. D., & Goldberg, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7812 · Cited by 358
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Welsh, S. J., & Corrie, P. G. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014566428 · Cited by 341
Venook, A. P., Niedzwiecki, D., Innocenti, F., Fruth, B., Greene, C., O'Neil, B. H., Shaw, J. E., Atkins, J. N., Horvath, L. E., Polite, B. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3504 · Cited by 336
Self-citationMechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 302
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 244
Immune Checkpoint Inhibitor Toxicity in 2018
Johnson, D. B., Chandra, S., & Sosman, J. A. (2018) · JAMA · doi:10.1001/jama.2018.13995 · Cited by 239
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F., & Saltz, L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.201 · Cited by 224
Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. D. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 177
Mechanism of Action of Immunotherapy
Disis, M. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.004 · Cited by 175
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Rosen, L. S., Jacobs, I. A., & Burkes, R. L. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0518-1 · Cited by 168
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N. C., Price, T. J., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 139
Cutsem, E. V., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H. A. J., Vermorken, J. B., Viret, F., Glimelius, B. L. G., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 134
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 133
Predictors of survival in stage IV metastatic colorectal cancer.
Zacharakis, M., Xynos, I. D., Lazaris, A. C., Smaro, T., Kosmas, C., Dokou, A., Felekouras, E. S., Antoniou, E., Polyzos, A., Sarantonis, J., et al. (2010) · PubMed · Cited by 123
Yarom, N., & Jonker, D. J. (2011) · PubMed · Cited by 110
Yang, S. Y., Cho, M. S., & Kim, N. K. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1442217 · Cited by 103
Kopetz, S., McDonough, S. L., Morris, V. K., Lenz, H., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Wang, S. E., Lieu, C. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.520 · Cited by 102
Multisciplinary management of patients with liver metastasis from colorectal cancer
Greef, K. E. D., Rolfo, C. D., Russo, A., Chapelle, T., Bronte, G., Passiglia, F., Coelho, A., Papadimitriou, K., & Peeters, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7215 · Cited by 97
Tang, P. A., Cohen, S. J., Kollmannsberger, C., Bjarnason, G. A., Virik, K., MacKenzie, M. J., Lourenço, L., Wang, L. E., Chen, A. P., & Moore, M. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3252 · Cited by 93
Clinical implications of microsatellite instability in sporadic colon cancers
Sinicrope, F. A., & Sargent, D. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832c94bd · Cited by 91
Folprecht, G., Pericay, C., Saunders, M. P., Thomas, A., López‐López, R., Roh, J. K., Chistyakov, V., Höhler, T., Js, K., Hofheinz, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw176 · Cited by 91
Le, D. T., Kavan, P., Kim, T. W., Burge, M., Cutsem, E. V., Hara, H., Boland, P. M., Laethem, J. V., Geva, R., Taniguchi, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3514 · Cited by 84
Kafatos, G., Niepel, D., Lowe, K., Jenkins-Anderson, S., Westhead, H., Garawin, T., Traugottova, Z., Bilalis, A., Molnar, E., Tímár, J., et al. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0358 · Cited by 53
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies
Riechelmann, R. P., & Grothey, A. F. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016676703 · Cited by 43
Cohn, A. L., Shumaker, G., Khandelwal, P., Smith, D. A. B., Neubauer, M., Mehta, N. D., Richards, D., Watkins, D. L., Zhang, K., & Yassine, M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.022 · Cited by 40
Cutsem, E. V., Cuyle, P.-J. A., Huijberts, S. C. F. A., Yaeger, R. D., Schellens, J. H. M., Élez, E., Tabernero, J. M., Fakih, M., Montagut, C. O., Peeters, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.627 · Cited by 36
Martinelli, E., Troiani, T., Sforza, V., Martini, G., Cardone, C., Vitiello, P. P., Ciardiello, D., Rachiglio, A. M., Normanno, N., Bianchi, A. S., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000299 · Cited by 35
Carter, N. J. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0140-6 · Cited by 26
Cited by
Colorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Larionova, I., Tuguzbaeva, G., Ponomaryova, A., Stakheyeva, M., Cherdyntseva, N., Pavlov, V., Choinzonov, E., & Kzhyshkowska, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566511 · Cited by 392
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
Wang, L., Li, S., Luo, H., Lu, Q., & Yu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02477-0 · Cited by 271
Metadata
- Authors
- Piawah, S., & Venook, A. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2019-08-21
- Volume
- 125
- Issue
- 23
- Pages
- 4139-4147
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2969669738
- Cited by
- 488
- References
- 65
- FWCI
- 18.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.